Navigation Links
Viroblock SA Reports a 99% Boost of Efficacy of Facemasks Against H5N1
Date:5/5/2009

PLAN-LES-OUATES, Switzerland, May 5 /PRNewswire/ -- Viroblock SA announces that its antiviral products boosts the efficacy of facemasks by at least 99.0%, i.e. 100 times better and a peak performance of 1000 times, against avian influenza virus H5N1. Disposable facemasks are thus far not very effective against viruses, such as influenza, whose sizes are 0.02 to 0.3 microns.

Its patented technology (VCCD Tech) potentially inactivates all families and strains of enveloped viruses, like human, avian and swine Influenzas, SARS, AIDS, Ebola and smallpox viruses. VCCD Tech uses a mechanism of action that greatly limits the development of any viral resistance.

The test involved flowing air contaminated with the aerosolized avian Influenza H5N1 virus through a set of pre-impregnated facemasks. Airstreams that passed through facemasks (percolation) were then analyzed for the presence of residual infectious virus. Performance was compared to non-impregnated facemasks. This series of tests was performed at Retroscreen Virology Ltd, a recognized world leader in the research and testing of antiviral compounds and vaccines.

"We are very pleased by the excellent results obtained during the last 6 months. In-vivo campaigns (ferrets) have recently demonstrated the efficacy of VCCD Tech as an antiviral intranasal spray and this latest series of tests shows the stunning performance of our formulations on facemasks. Meanwhile the most recent ex-vivo screening campaigns prove its efficacy on additional viruses.

"H5N1 is just one of a number of emerging viruses such as SARS, and lately the swine flu, which represent a genuine threat across the globe. Viroblock has the technology platform to contribute to the development of new and innovative antiviral countermeasures, such as facemasks to protect not only frontline and government staff such as nurses, doctors, paramedics, firemen and police officers, but also the general public. I believe that Viroblock has all the assets to become a key player in pandemic influenza preparedness efforts," comments CEO Thierry Pelet.

"All these results establish the broad spectrum of action of VCDD Tech against enveloped viruses and the flexibility in its deployment. Our technology is a breakthrough for inactivating enveloped viruses and their strains; I am convinced that we have not yet exploited all its potential. I am pleased to be part of an outstanding team that works tirelessly to develop and fully exploit our technology platform," added Francois Gilardoni, member of the Board.

About Viroblock SA

Viroblock SA is a Swiss start-up founded in 2005, which has become a pioneer and world leader in the blocking virus transmission technology. Viroblock was founded by Dr. Donald F. H. Wallach who was a worldwide expert in artificial and bio-membranes, and non-phospholipid vesicles.

Its patented VCCD technology is suitable for solid supports, colloidal suspensions, emulsions, and aerosol sprays.

    Additional information is available on the company's website at
http://www.viroblock.com

    Contact:
    Dr. Thierry Pelet
    Chief Executive Officer
    Viroblock SA
    Phone: +41-22-884-8344
    E-Mail: info@viroblock.com



'/>"/>
SOURCE Viroblock SA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
(Date:4/25/2017)... ... 2017 , ... As pharmaceutical companies are held to increasingly ... innovation in drug formulation and manufacturing. CoreRx offers its clients more than ... support of their development and manufacturing goals. , The company was created ...
(Date:4/25/2017)... Scotch Plains, NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD ... with the treatment of acute or chronic problems, I focus on preventative care with all ... patient. If you have any questions, always feel free to contact my office and my ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: